The new Alzheimer's drug of Beijing New Pharmaceutical Co., Ltd. kabalatin bitartrate capsule is expected to be approved this year
-
Last Update: 2015-01-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on the website of the State Food and Drug Administration (CFDA), Beijing new pharmaceutical's cabalatine heavy tartrate capsule was applied for acceptance in June 2011, which has lasted for more than three years At present, the domestic market of kabalatin bitartrate is monopolized by Novartis The enterprises in the process of product research and development also include Enhua pharmaceutical, Huahai pharmaceutical, Shanghai Sanwei pharmaceutical, vante pharmaceutical, etc According to the public information, carbalatin bitartrate is an acetylcholinesterase inhibitor, which is the mainstream drug for the treatment of Alzheimer's disease The original manufacturer is Novartis The experimental data showed that kabalatin tartrate was well tolerated to mild and moderate Alzheimer's disease due to no metabolism of liver and P450 (cytochrome) It was highly evaluated in a prospective, randomized, multicenter, double-blind study conducted in 45 countries including Europe and the United States Before Beijing New Pharmaceutical Co., Ltd went public, it mainly engaged in fluoroquinolones as raw materials for anti infective drugs Through many years of operation, it has actively transformed into preparations At present, the gross profit contribution rate of preparation business has exceeded that of raw materials and become the main profit contribution source of the company.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
